BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 9190996)

  • 1. Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissues.
    Han AC; Peralta-Soler A; Knudsen KA; Wheelock MJ; Johnson KR; Salazar H
    Hum Pathol; 1997 Jun; 28(6):641-5. PubMed ID: 9190996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies.
    Abutaily AS; Addis BJ; Roche WR
    J Clin Pathol; 2002 Sep; 55(9):662-8. PubMed ID: 12194995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas: a ThinPrep immunocytochemical study.
    Han AC; Filstein MR; Hunt JV; Soler AP; Knudsen KA; Salazar H
    Cancer; 1999 Apr; 87(2):83-6. PubMed ID: 10227598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma.
    Oates J; Edwards C
    Histopathology; 2000 Apr; 36(4):341-7. PubMed ID: 10759948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas.
    Peralta Soler A; Knudsen KA; Jaurand MC; Johnson KR; Wheelock MJ; Klein-Szanto AJ; Salazar H
    Hum Pathol; 1995 Dec; 26(12):1363-9. PubMed ID: 8522310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. E-cadherin, E-selectin and vascular cell adhesion molecule: immunohistochemical markers for differentiation between mesothelioma and metastatic pulmonary adenocarcinoma?
    Müller AM; Weichert A; Müller KM
    Virchows Arch; 2002 Jul; 441(1):41-6. PubMed ID: 12111199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma.
    Ordóñez NG
    Am J Surg Pathol; 1998 Oct; 22(10):1215-21. PubMed ID: 9777983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of E-cadherin and N-cadherin immunostaining in the diagnosis of mesothelioma.
    Ordóñez NG
    Hum Pathol; 2003 Aug; 34(8):749-55. PubMed ID: 14506634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.
    Ordóñez NG
    Am J Clin Pathol; 1998 Jan; 109(1):85-9. PubMed ID: 9426522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma.
    Leers MP; Aarts MM; Theunissen PH
    Histopathology; 1998 Mar; 32(3):209-16. PubMed ID: 9568505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinguishing malignant mesothelioma from pulmonary adenocarcinoma: an immuno-histochemical approach using a panel of monoclonal antibodies.
    Tuttle SE; Lucas JG; Bucci DM; Schlom J; Primus J
    J Surg Oncol; 1990 Oct; 45(2):72-8. PubMed ID: 2214794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed and paraffin wax embedded material.
    Edwards C; Oates J
    J Clin Pathol; 1995 Jul; 48(7):626-30. PubMed ID: 7560168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in lectin binding of malignant pleural mesothelioma and adenocarcinoma of the lung.
    Kawai T; Greenberg SD; Truong LD; Mattioli CA; Klima M; Titus JL
    Am J Pathol; 1988 Feb; 130(2):401-10. PubMed ID: 2449084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I: Immunohistochemical findings.
    Moch H; Oberholzer M; Dalquen P; Wegmann W; Gudat F
    Virchows Arch A Pathol Anat Histopathol; 1993; 423(1):19-27. PubMed ID: 8212530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12.
    Lee I; Radosevich JA; Chejfec G; Ma YX; Warren WH; Rosen ST; Gould VE
    Am J Pathol; 1986 Jun; 123(3):497-507. PubMed ID: 3717302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TTF-1 and surfactant-B as co-adjuvants in the diagnosis of lung adenocarcinoma and pleural mesothelioma.
    Bakir K; Koçer NE; Deniz H; Güldür ME
    Ann Diagn Pathol; 2004 Dec; 8(6):337-41. PubMed ID: 15614737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas.
    Tot T
    Cancer; 2001 Nov; 92(10):2727-32. PubMed ID: 11745209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.
    Sheibani K; Battifora H; Burke JS
    Am J Pathol; 1986 May; 123(2):212-9. PubMed ID: 2422942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of snail, twist, and Zeb1 in malignant mesothelioma.
    Merikallio H; Pääkkö P; Salmenkivi K; Kinnula V; Harju T; Soini Y
    APMIS; 2013 Jan; 121(1):1-10. PubMed ID: 23030626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of membranous staining of mesothelioma.
    King JA; Tucker JA
    Cell Vis; 1998; 5(1):24-7. PubMed ID: 9660721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.